High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy

Table 6 Clinical features of patients treated with postoperative radiotherapy

Nr.	Age	Sex	Site	Size	Diag	Margin	FU/m	Met/m	Met/s	status
4	31	M	4	9	3	Marginal	16	3	Lung	DOD
30	33	M	4	18	4	Wide	23	11	Multi	DOD
63	55	M	2	12	1	Wide	23	14	Lung	DOD
64	60	M	4	10	1	Wide	44	11	Lung	NOD
82	67	M	4	8.5	1	Marginal	15	3	Multi	DOD
137	61	M	1	10	1	Marginal	32	30	Lung	DOD
144	63	M	4	20	1	Wide	6	4	Lung	DOD
145	68	M	5	11.5	1	Marginal	81	64	Lymph	NOD
160	21	M	4	11	2	Marginal	31	21	Multi	DOD
165	31	F	2	15	2	Marginal	15	3	Multi	DOD
178	32	M	4	10	2	Wide	18	16	Multi	DOD
190	58	M	4	12	3	Marginal	24	12	Multi	DOD
198	54	F	1	13	2	Marginal	120	6	Lung	NOD
227	71	F	4	12	5	Marginal	39	38	Multi	DOD
239	27	M	2	9.5	5	Wide	33	31	Lymph	DOD
328	31	M	2	10	3	Marginal	8	4	Os	DOD

Average tumour size was 12 cm. Average follow-up was 33 months. Pat. Nr. 63, 64 and 198 underwent thoracotomy for lung metastasis resection. Pat. 64 developed local recurrence (treated with limb sparing surgery) 2 months prior to metastasis. Pat. 137 developed local recurrence after 6 months (treated with limb sparing surgery) and metastatic disease 24 months later. Pat. 190 developed local recurrence two months after metastatic disease occurred and palliative treatment had been initiated. Pat. 82, 145 and 239 were resected for regional lymph node metastasis. Pat. 82 and 239 developed progredient disease with further metastasis under palliative treatment.
Abbreviations: Sex: F = female, M = male site: 1 = upper extremity 2 = pelvis 3 = groin 4 = thigh 5 = popliteal fossa 6 = shank diagnosis: 1 = malignant fibrous histiocytoma 2 = leiomyosarcoma 3 = liposarcoma 4 = synovial sarcoma 5 = neurogenous sarcoma
FU/m: Follow-up/months
Met/m: Manifestation of metastatic disease/months after tumour resection
Met/s: Anatomical localisation of metastasis
status: DOD = died of disease NOD = no evidence of disease

ISSN: 1471-2407